SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): December 17, 2017
SPECTRUM PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction
11500 S. Eastern Ave., Ste. 240
Henderson, NV 89052
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (702) 835-6300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a12)|
|☐||Pre-commencement communication pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b), (c) and (d)
On December 17, 2017, the Board of Directors (the Board) of Spectrum Pharmaceuticals, Inc. (the Company) terminated the employment of Rajesh C. Shrotriya, M.D., the Companys then Chief Executive Officer, without cause in accordance with his employment agreement with the Company, which was previously filed with the Securities and Exchange Commission. The termination was effective immediately and will entitle Dr. Shrotriya to payments and severance benefits as set forth in his employment agreement for a termination without cause.
In connection with the termination of Dr. Shrotriya, the Board appointed Joseph W. Turgeon, the Companys then President and Chief Operating Officer, as President and Chief Executive Officer, and Thomas J. Riga, the Companys then Executive Vice President, Chief Commercial Officer and Head of Business Development, as Chief Operating Officer, in each case effective immediately. Mr. Turgeon will serve as the Companys principal executive officer for purposes of the Securities Exchange Act of 1934, as amended (the Exchange Act). The Boards decisions with respect to the management changes described in this Current Report on Form 8-K were based on its views as to who was in the best position to lead the Company going forward.
In addition, the Board increased the size of the Board to eight members and appointed Mr. Turgeon to the Board to fill the newly created directorship, effective immediately. The Board has also named current director Stuart M. Krassner as Chairman of the Board, effective immediately.
The compensation that Mr. Turgeon will receive in his role as Chief Executive Officer and Mr. Riga will receive in his role as Chief Operating Officer of the Company has not yet been determined, and an amendment to this Current Report on Form 8-K will be filed at a later date to disclose such compensation when a determination has been made.
Mr. Turgeon has served as President and Chief Operating Officer since April 2014 and previously served as Senior Vice President and Chief Commercial Officer from October 2012 to April 2014. He brings more than 30 years of pharmaceutical sales experience, including various executive leadership roles at Amgen Inc. Prior to joining the Company, Mr. Turgeon spent 22 years at Amgen Inc., including as Vice President of Sales. Mr. Turgeon holds a Bachelor of Science in Microbiology and Economics from Jacksonville University.
There are no family relationships between Mr. Turgeon and any director or executive officer of the Company, or any person nominated or chosen by the Company to become a director or executive officer. There are no arrangements or understandings between Mr. Turgeon and any other persons pursuant to which he was selected as Chief Executive Officer. Mr. Turgeon has no direct or indirect material interest in any transaction or currently proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Mr. Riga has served as Executive Vice President, Chief Commercial Officer and Head of Business Development since June 2017 and previously served as Senior Vice President and Chief Commercial Officer from August 2014 to June 2017, and Vice President, Corporate Accounts from July 2013 to August 2014. Prior to joining the Company, Mr. Riga served as Vice President of Sales at Dendreon Pharmaceuticals LLC, a biotechnology company, from April 2012 to June 2013. Mr. Riga has also held various managerial positions in sales, marketing and manufacturing at Amgen, Eli Lilly and Wyeth Ayerst, all pharmaceutical companies. Mr. Riga holds a Bachelors degree in Biology and Chemistry from St. Lawrence University.
There are no family relationships between Mr. Riga and any director or executive officer of the Company, or any person nominated or chosen by the Company to become a director or executive officer. There are no arrangements or understandings between Mr. Riga and any other persons pursuant to which he was selected as Chief Operating Officer. Mr. Riga has no direct or indirect material interest in any transaction or currently proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
|Item 7.01.||Regulation FD Disclosure|
A copy of the press release issued by the Company on December 17, 2017 relating to the matters described in this 8-K, among other matters, is attached hereto as Exhibit 99.1.
Note: The information furnished herewith pursuant to Item 7.01 of this current report shall not be deemed to be filed for the purpose of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
|Item 9.01||Financial Statements and Exhibits|
|99.1||Press Release, dated December 17, 2017.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: December 18, 2017||SPECTRUM PHARMACEUTICALS, INC.|
|Kurt A. Gustafson,|
|Executive Vice President and Chief Financial Officer|
Spectrum Pharmaceuticals Announces Leadership Changes
Joseph W. Turgeon Named President and CEO and Elected to the Board of Directors
Thomas J. Riga Named Chief Operating Officer
Stuart M. Krassner, ScD, PsyD Named Chairman of the Board
HENDERSON, Nevada (December 17, 2017) Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its Board of Directors has terminated Rajesh C. Shrotriya, MD without cause from his position as Chief Executive Officer, and announced leadership changes under which Joseph W. Turgeon, the current President and Chief Operating Officer, has been named President and Chief Executive Officer and elected to the Board of Directors, and current Director Stuart M. Krassner, ScD, PsyD, has been named Chairman of the Board. In addition, Thomas J. Riga, who currently serves as Executive Vice President, Chief Commercial Officer and Head of Business Development, has been named Chief Operating Officer. These changes are effective immediately.
The Board of Directors thanks Dr. Shrotriya for his contributions to Spectrum over the past fifteen years, said Dr. Krassner, Chairman. The Board believes that now is the right time to effect these leadership changes. Mr. Turgeon and Mr. Riga have nearly 50 years of combined industry experience and the Board believes that they are the right leaders for Spectrum as the Company enters its next chapter.
I am honored to serve as Spectrums next CEO and appreciate the confidence the Board has placed in me to guide the Company forward, said Mr. Turgeon, President and CEO. We are at an exciting point in Spectrums history, and I look forward to driving the operation forward as we maintain our focus on our product pipeline.
Mr. Turgeon brings more than 30 years of experience in the pharmaceutical industry, including various executive leadership roles at Amgen Inc. He had served as Spectrums President and Chief Operating Officer since April 2014, and had previously served as the Companys Senior Vice President and Chief Commercial Officer from October 2012 to April 2014. Prior to joining Spectrum, Mr. Turgeon spent 22 years at Amgen Inc. as Vice President of Sales.
Mr. Riga brings over 15 years of pharmaceutical sales and management experience in various positions at Amgen, Eli Lilly and Dendreon, including as Vice President of Sales at Dendreon. He had served as Spectrums Executive Vice President , Chief Commercial Officer and Head of Business Development since June 2017, and previously served as Spectrums Senior Vice President and Chief Commercial Officer from August 2014 to June 2017, and Vice President, Corporate Accounts from July 2013 to August 2014.
Dr. Krassner has served as a director of Spectrum since December 2004, and was previously a member of Spectrums Scientific Advisory Board from 1996 to 2001. Dr. Krassners career spans nearly four decades of experience in positions of increasing responsibility at the University of California at Irvine, most recently as Professor of Developmental and Cell Biology at the School of Biological Sciences. Dr. Krassner is Professor Emeritus, University of California, Irvine and has also been retained by pharmaceutical, medical device and other companies, including Allergan Pharmaceuticals, Lasermed
Corporation, Automated Microbiology Systems, and In Vitro International, among others, to provide scientific and regulatory advisory services, including FDA compliance. He is a past member of the American Academy for the Advancement of Sciences, and the American Society of Tropical Medicine and Hygiene, among others.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the Company. Spectrums strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on managements current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrums business and its future, including Spectrums ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrums existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Companys reports filed with the Securities and Exchange Commission. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Sard Verbinnen & Co
Peter Siwinski/Paul Frankle